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Abstract: Psoriasis is a frequent inflammatory disease with a chronic and relapsing course. 
Therefore, patients with psoriasis are likely to undergo different treatments for long periods of 
time. Traditionally, therapies used in psoriasis have been associated with poor levels of adherence 
due to the complexity of the regimens and the poor results obtained with the topical therapies. 
These poor outcomes are associated with high levels of frustration and anxiety, which decrease 
adherence and worsen the disease. With the recent introduction of highly efficacious biologic 
therapies, patients can achieve very good and prolonged responses. However, most patients 
with psoriasis have mild disease and may be treated with skin-directed therapies. Therefore, it 
is important to develop strategies to improve adherence in order to achieve better outcomes, 
and to improve the overall quality of life. Hence, acknowledging the causes of nonadherence is 
crucial for implementing these strategies. In this summary, we review the causes of nonadher-
ence, and we provide behavioral strategies in order to improve adherence and, ultimately, the 
outcome of patients with psoriasis.
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Introduction
Psoriasis is a frequent inflammatory disease affecting approximately 2% of the popu-
lation in western countries.1 Psoriasis can affect either young or elderly people, and 
it has a chronic and relapsing course. Therefore, patients with psoriasis are likely to 
undergo different treatments for long periods of time. Traditionally, therapies used 
in psoriasis have been associated with poor levels of treatment adherence due to the 
complexity of the regimens and the poor results obtained with topical therapies.2 These 
poor outcomes are associated with high levels of frustration, anxiety, and depression, 
which worsen the disease due to both a direct effect of stress in the immune system3 
and a decrease in treatment adherence. With the recent introduction of highly effica-
cious biologic therapies, patients can achieve very good and prolonged responses. 
However, most patients with psoriasis have mild disease and may be treated more 
likely with skin-directed therapies.
Therefore, it is crucial to develop strategies to improve adherence in order to 
achieve better outcomes, prevent flares, control the comorbidities associated with pso-
riasis, and improve the overall quality of life (QoL) of patients with psoriasis. Hence, 
acknowledging the causes of nonadherence is fundamental to be able to implement 
these strategies. In the present article, we will review the causes of nonadherence and 
provide strategies to improve treatment adherence in patients with psoriasis.
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Methods
We have performed a literature search in Medline using the 
keywords “(psoriasis OR dermatology) AND (adherence OR 
compliance)”. This search prompted 1,627 articles that were 
selected according to their relevance by reviewing the avail-
able abstracts. Articles were selected if they provided clear 
definitions on terms such as adherence and compliance, or 
if they reviewed factors that influence or modify adherence. 
We also searched for specific keywords such as adherence, 
compliance, persistence, psychological impact, and psycho-
logical evaluation in psoriasis. In total, 75 articles were read 
and reviewed and, finally, 49 were included in the current 
manuscript. We have classified the causes of nonadherence 
in three categories, depending on if they were linked with 
factors related to the therapies, factors related to the patient, 
and factors related to the patient–physician relationship. For 
each of these categories, measures to increase adherence 
were also suggested.
Adherence in psoriasis
Adherence is a complex human behavior modulated by 
subjective components. As the name suggests, adherence 
is associated with being voluntarily attached to something 
in a constant manner.4 Generally, adherence is poorer in 
chronic diseases, with treatments that are difficult to apply, 
with preventive measures, or preventive strategies. Thus, it 
is easy to understand why adherence in dermatology is poor, 
as it is due to the relapsing nature of the most common skin 
diseases and the use of multiple topical treatments which, 
in most cases, are not applied correctly. In fact, Storm et al5 
noted that 95% of patients with skin problems that were seen 
for the first time in a dermatology department underdosed 
their topical therapies. Patients with psoriasis are not an 
exception and show poor adherence to treatments.2
Nonadherence is a major economical concern, as it asso-
ciated with more costs, both direct and indirect. Bad adher-
ence in psoriasis is associated with worse disease control and 
it may require the use of more potent and expensive drugs; 
it may also have a direct impact on societal productivity. 
Patients with a bad control of their psoriasis will require 
more appointments with their health care providers, and 
therefore will be more prone to losing job days and being less 
productive. Thus, improving adherence is a must, as strate-
gies that improve adherence are related to a better control 
of the disease.6
Nonadherence can be divided into intentional and unin-
tentional, depending on which motivations lead the patient to 
not follow a certain therapy.7 Unintentional nonadherence is 
mainly related to problems with applying treatments, errors 
in understanding the prescription, and forgetting to apply 
or take medications. Conversely, intentional nonadherence 
occurs when patients deliberately decide not to continue on 
a certain therapy. This can be due to preexisting psychopa-
thology, although it is most frequently due to communication 
problems between patients and their physicians or due to poor 
results with their current therapies.8 Nonadherence can also 
be divided into primary and secondary. Primary nonadher-
ence refers to not redeeming prescriptions and not starting 
a treatment, whereas secondary nonadherence refers to not 
using the medications correctly.9 An additional concept linked 
to secondary nonadherence is persistence, which refers to 
the continuous use of a treatment and not stopping it earlier 
than prescribed.10 In psoriasis, both primary and second-
ary nonadherence are poor, with less than 50% of patients 
redeeming their prescriptions11 and only one- to two-thirds 
of patients using the medication correctly.11–15
Hence, adherence is influenced by multiple behavioral 
factors. In addition, psoriasis is a condition with a very 
important psychosomatic component, which can worsen the 
disease when high levels of stress are present, due to poor 
adherence but also due to a direct effect of stress on the out-
come of the disease.16 Therefore, in patients with suspected 
poor adherence or poor outcomes, it can be useful to evaluate 
the psychological impact of psoriasis.
Psoriasis, psychological impact, and 
influence on treatment adherence
Psoriasis is associated with a strong psychological impact 
due to its visibility and a chronic and relapsing course.17–19 
The disfigurement in psoriasis decreases self-esteem,16 and 
induces the onset of stigmatization and the anticipation to 
rejection.20 This is associated with high stress levels, anxi-
ety, depressive symptoms, and changes in behavior, such as 
toxic habits or poor adherence to treatments.12,17,21 Stress 
increases proinflammatory cytokines, which interact with 
the lymphocytes, and produces a suppressive effect in the 
immune system.3 At the same time, these cytokines induce 
depressive symptoms and anxiety, which can trigger psoriasis 
flares and also reduce adherence. Thus, psoriasis is a good 
example of a psychosomatic disease,16 as psoriasis increases 
the levels of stress and anxiety and, at the same time, stress 
worsens the clinical course of the disease. Therefore, an 
early evaluation and treatment of the psychological impact 
in patients with psoriasis is crucial to implement strategies 
to improve adherence to treatment and ultimately improve 
the clinical outcome.
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Several tests are currently available to evaluate the 
psychological impact of psoriasis. As previously stated, 
QoL can be severely decreased in patients with psoriasis. In 
order to evaluate QoL, the Dermatology Life Quality Index 
(DLQI)22 is the most commonly used QoL evaluation tool in 
psoriasis. However, the results can vary between countries 
due to cultural differences. Therefore, the use of an additional 
test may be useful in patients with important psychological 
burden. A good complementary test is Skindex 16 that, on one 
page, includes 16 items that evaluate how much patients are 
bothered by their skin conditions.23 The evaluation of QoL is 
fundamental, as very impaired QoL may be associated with 
poor adherence and poor outcomes and may be the indication 
for biologic drugs.24–26
In addition, in select patients, it may be useful to screen 
for potential psychiatric disorders such as depression, anxiety, 
and alcohol abuse, which are associated with poor adherence. 
The prevalence of depression in patients with psoriasis is 
approximately 30%, with up to 10% of patients reporting sui-
cidal ideation.27 Therefore, it is crucial to ask about depressive 
symptoms in patients with psoriasis. It is especially important 
to investigate the presence of anhedonia (not being capable of 
enjoying those things that are commonly pleasurable), as this 
is probably the most useful clue to screen for depression. In 
cases with suspected depression, good screening tests include 
the Hospital Anxiety and Depression Scale (HADS)28 and the 
Goldberg Depression and Anxiety Scale.29
Eventually, patients with psoriasis may have increased 
their consumption of alcohol, especially if their psoriasis 
is moderate or severe, and this is associated with poor 
adherence.30 Therefore, to screen for alcohol misuse, we 
recommend using the Alcohol Use Disorders Identification 
Test (AUDIT), which is a simple ten-item test with high 
sensitivity and specificity to detect harmful alcohol use.31 
Regardless of the health benefits associated with alcohol 
cessation in patients with heavy alcohol use, in the specific 
setting of psoriasis, alcohol cessation is especially relevant, 
as alcoholism is associated with worse outcomes, worse 
adherence to treatment, more severe disease,30 increased risk 
of fatty liver (which may limit the use of certain drugs such 
as methotrexate),32 and even increased risk of mortality.33
Hence, in patients with suspected poor adherence, it 
may be advisable to evaluate their QoL and to screen for 
depression, anxiety, and heavy alcohol use. If this evalu-
ation disclose psychosocial comorbidities, patients should 
be referred to a psychologist or psychiatrist in order to 
improve adherence, and also to screen for psychopathologi-
cal comorbidities.34 However, certain situations may require 
professional psychological evaluation regardless of the test 
results, such as adjustment disorders, suicidal ideation, onset 
of the disease related to stress in adolescents or young adults, 
poor clinical response due to bad adherence, and extreme 
concern in relation to the severity of the psoriasis.17,34
Causes of nonadherence and 
measures to increase adherence
Despite the impact of psychosomatic comorbidities, other 
causes can also influence adherence in patients with psoriasis. 
From a practical standpoint, nonadherence can be influenced 
by factors related to patient characteristics and beliefs, 
patient–physician relationship, and treatment.12 All of these 
factors should be acknowledged and identified by health 
care providers to implement strategies to increase adherence, 
maintain long-term persistence, and ultimately improve the 
outcome of patients with psoriasis. Although some of these 
factors cannot be changed, identifying individuals at a higher 
risk of nonadherence can be beneficial when deciding the best 
therapeutic approach for each patient. In subsequent sections, 
and in Table 1, we summarize the causes of nonadherence, 
and we discuss possible strategies to improve adherence in 
patients with psoriasis.
Table 1 Strategies to improve adherence in patients with 
psoriasis
Strategies related to the patient
– Health education 
 • To the patient 
 • Public campaigns 
– Alcohol/tobacco cessation 
 – Psychotherapy 
 •  Relaxation techniques 
 •  Disease coping techniques 
 • Support groups 
– Psychiatry referral if psychopathology
Strategies related to the patient–physician relationship
– Pleasant and friendly attitude 
– visual contact 
– empathy 
– Trusting relationship with the patient 
– Active listening 
– Agreed therapeutic regimens 
– Avoidance of medical jargon
Strategies related to the therapy
– Feasible to apply in patients with extensive involvement 
–  High efficacy 
– Low cost 
– Nongreasy, clean, nonsmelling, nonstaining (gels, foams, lotions) 
– infrequent application/intake (weekly, monthly) 
– Minimal adverse effects 
– written instructions
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Factors related to the patient
Certain demographic factors have been associated with worse 
adherence and include male sex, unemployment, singleness, 
and heavy alcohol and tobacco consumption.35 Adherence 
is also poorer in patients with severe psoriasis compared to 
patients with mild psoriasis.35 These patients have a worse 
psychological impact and may not rely on therapies, leading 
to a decrease in adherence.12,36 The more severe impact of 
psoriasis is that it also determines lower salaries, as patients 
with visible psoriasis will not be hired for certain positions, 
or they will not even apply for certain jobs. In addition, the 
low income associated with this situation will have a nega-
tive impact on adherence, as some patients will not be able 
to afford expensive medications.17 Hence, public campaigns 
to raise awareness of psoriasis can be performed in order to 
eliminate the stigmatization associated with the disease and 
to provide more equal opportunities for all the individuals 
in society.
In addition, patients that have a limited income, live alone, 
or engage in heavy alcohol consumption are more likely to 
have anxious and depressive symptoms, which will worsen 
their psoriasis and make it difficult to gain adequate control of 
the disease. Thus, in patients with psoriasis, it is fundamental 
to identify the presence of associated psychopathology or 
substance abuse using the aforementioned tools in order to 
provide adequate referral and treatment. Also, in patients 
with high stress levels and poor social support, psychotherapy 
has proven to be effective in order to improve adherence.37–39 
Psychological strategies that may be useful include relaxation 
techniques, strategies to cope with the disease, and support 
groups. In select cases with severe psychopathology, the use 
of psychoactive drugs may also be beneficial.40
Coping with the disease is fundamental to improving 
adherence. Initially, when psoriasis is diagnosed, most 
patients are not fully aware of the chronic and relapsing 
course of the disease. Thus, it is fundamental to give adequate 
information about the disease, focusing on the chronic 
nature of psoriasis and that the treatment goal is controlling 
the symptoms rather than curing the disease. Also, patients 
should be informed that therapies will likely be used for pro-
longed periods of time. This will give realistic expectations 
to the patients about what to expect with their therapies and 
the drug-related side effects. Ultimately, this approach will 
prevent patients from developing maladaptive behaviors such 
as denial of the disease or fear of side effects, which may 
result in bad adherence.41
Forgetting to take medications is also a main issue related to 
poor adherence, and several strategies can be used as reminders, 
such as text messages,8 emails, or phone calls. In that sense, 
nurses are being increasingly more involved in becoming a 
key part of the treatment of patients with psoriasis,42 not only 
by helping them with treatment reminders but also by helping 
patients when they have doubts about how to apply the medica-
tion, and by giving important information about the disease.
Factors related to the patient–physician 
relationship
In a recent study, patients with psoriasis stated that they 
considered their disease dirty, and that this was not taken 
into account by their physicians.8 In addition, patients con-
sidered that their physicians did not pay enough attention to 
prescribing adequate treatments for their disease. Although 
these perceptions are not always true, an optimal relationship 
between the patient and his or her health care providers is 
fundamental to enhance adherence.43,44 A bad relationship 
between the patient and his or her physicians may lead to a 
loss of trust toward medications and health care providers, 
and it has a negative impact on adherence. An important 
percentage of patients may have unrealistic expectations 
related to therapy, and therefore physicians should provide 
realistic therapeutic goals to their patients.8
It is also important to identify certain patterns associ-
ated with adherence in patients with psoriasis. Adherence 
improves in the days before and after the appointment with 
the physician.45 Therefore, performing an early follow-up visit 
with the patient is an excellent opportunity to improve the 
patient–physician relationship and to increase adherence.12 
However, a recent study showed that not a lot of physicians 
use this strategy, which is obviously a missed opportunity to 
improve adherence in dermatologic conditions.46
Another issue that decreases adherence is not considering 
patients’ beliefs, expectations, or preferences.8 Therefore, 
agreeing to and reassuring the therapy and the regimen with 
the patient according to his or her preferences is fundamental 
to increasing treatment adherence.47 Therefore, paternalistic 
or defensive attitudes should be avoided, as they will worsen 
the relationship between the patient and the physician. In 
addition, certain strategies can be implemented to improve 
this relationship, such as avoiding the use of medical jargon, 
showing a pleasant and empathetic attitude toward the patient, 
and providing a cooperative environment in order to discuss 
the best treatment options for each patient.
Factors related to the treatment
Nonadherence related to treatment is associated with a 
variety of factors. Factors associated with negative opinions 
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regarding treatments include greasy vehicles, excessive time 
needed to apply the treatment, fear of side effects, and slow-
acting treatments.8,12,14,17,21 For example, topical treatments 
are less preferred than systemic drugs or phototherapy, but 
they are considered safer.48 Overall, phototherapy and inject-
able drugs are treatments with higher patient satisfaction 
and adherence, not only because these treatments are more 
effective but also because patients are more involved in their 
treatments.49 In fact, making patients become more involved 
in their therapies has been associated with increased levels 
of adherence.44,50
However, differences exist within the same therapeutic 
modality. For example, within topical corticosteroids, the 
results obtained can vary depending on different factors, 
such as potency of the corticosteroid, the location where the 
treatment is applied, or the vehicle used. Regarding this last 
factor, traditional dermatologic knowledge has highlighted 
that thick vehicles such as ointments have better efficacy than 
lighter formulations. However, it has been shown that efficacy 
rates are similar between ointments and other formulations, 
such as creams, foams, shampoos, or lotions.51 In addition, 
the use of more cosmetic vehicles such as gels is preferred by 
patients and is associated with better adherence.52 Ideally, a 
topical treatment should be nongreasy, efficacious, safe, and 
feasible to apply to different anatomic areas. This is especially 
important in areas such as the scalp, where the application 
of foams, shampoos, or gels is preferred instead of the use 
of greasier vehicles.52 In fact, certain locations, such as the 
scalp or the nails, can be very troublesome because the lesions 
are highly visible and the application of topical treatments 
is difficult requiring, in some cases, the use of systemic 
therapies.52–55 Nevertheless, the decision as to which vehicle 
should be used should also rely on the patients’ preferences, 
as this will ultimately affect adherence.51
Another important factor to consider is the treatment 
regimen. In a survey where patients with psoriasis were asked 
about the reasons for not adhering to treatments, the most fre-
quent answer was that treatment had to be applied too often.12 
Therefore, simplifying the treatment21 and choosing stronger 
therapies with less frequent regimens is a good strategy to 
improve adherence. However, a special comment has to be 
made regarding treatments that are not applied or taken daily, 
such as systemic methotrexate or biologics. In these cases, 
ensuring that the patient understands the prescription, and that 
he or she is also given clear written or even graphical instruc-
tions on treatment regimens, can be helpful to improve adher-
ence and to prevent the development of side effects which, in 
certain circumstances, can be life threatening.32,56
Discussion
When poor adherence is suspected, it is important to ask 
for the patients’ preferences regarding different treatment 
options, as well as to explore the social background of the 
patient (social support, economic situation, substance abuse), 
and also to screen for the presence of anxiety or depressive 
symptoms. If nonadherence is noted, it is important to identify 
if nonadherence is intentional or unintentional, and not to 
blame the patient because this will further decrease adherence 
and final outcomes. On the other hand, discussing the reasons 
for not adhering to a therapy is a better approach if we want 
our patients to successfully use the prescribed therapies.
Even though psychological factors and personality traits 
are always important, the reasons for inadequate adherence 
in psoriasis differ according to the type of treatment. With 
respect to topical treatment, the main reasons for poor adher-
ence are perceived lack of efficacy, slow onset of effect, and 
inconvenience of application, due to its frequency and vehicle 
characteristics.57 In the case of conventional systemic drugs, 
the occasional skipping of doses is unlikely to be clinically 
relevant, but treatment discontinuation is generally associ-
ated with tolerability/safety issues (43%) or a lack/loss of 
effectiveness (30%).58 The main reason for nonfulfillment 
of biologic prescriptions (primary nonadherence) is con-
cern about potential adverse effects and safety issues, and 
discontinuation (secondary nonadherence) is due to toler-
ability/safety problems (25%), a lack or loss of effectiveness 
(22%), injection reactions or inconvenience (10%), and cost/
insurance reimbursement issues (11%).58 Treatment cessation 
because of an adequate response cannot be considered a lack 
of adherence, since the physician and/or the patient consider 
the treatment is no longer needed; this constitutes the basis 
for intermittent therapy. The same applies to dosage individu-
alization through the lengthening of administration intervals, 
which can be decided by the prescriber or the patient on 
his or her own accord, but it cannot be considered a lack of 
adherence since the therapeutic goal is maintained.
Conclusion
To sum up, psoriasis is a disease with an important psycho-
somatic background, in which stress plays an important role, 
not only with the onset of acute flares but also in the presence 
of associated comorbidities. The prevalence of psychological 
comorbidities is high and may require referral to a psycholo-
gist or psychiatrist if psychopathology is noted. Moreover, 
in order to improve adherence, a good relationship with 
patients is crucial, showing an empathetic approach toward 
our patients. A joint decision regarding which therapies 
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will be better in each case is essential to guaranteeing a 
successful outcome in our patients. Choosing therapies 
that are efficacious, safe, and easy to apply will enhance 
adherence. However, in some cases, a multidisciplinary, 
holistic approach involving psychologists, psychiatrists, 
rheumatologists, nurses, and other health care providers 
may be necessary.
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